MEDNAX (MD) Tops Q4 EPS by 14c ; Provides Outlook

MEDNAX (NYSE: MD) reported Q4 EPS of $0.51, $0.14 better than the analyst estimate of $0.37. Revenue for the quarter came in at $502 million versus the consensus estimate of $487.06 million.

Preliminary 2025 Outlook

On a preliminary basis, Pediatrix anticipates that its 2025 Adjusted EBITDA, as defined above, will be in a range of $215 million to $235 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Take-Two stock drops as GTA 6 leaks continue
• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short